Skip to main content
. 2022 Dec 26;24:263–312. doi: 10.1016/j.bioactmat.2022.12.014

Fig. 16.

Fig. 16

Nanomaterials as active targeting drug carriers. A) Preparation and characterization of PAB and CLT-PAB NPs. (i) Schematic displaying the proposed mechanism by which CLT-PAB NPs target SR-A during treatment of rheumatoid arthritis [181]. The image reproduced with the permission from Elsevier Ltd. B) Schematic representation of MTX-conjugated polymer hybrid micelles co-loaded with miR-124 (M-PHMs/miR-124) preparation and combination therapy of M-PHMs/miR-124 in RA [182]. The image reproduced with the permission from Ivyspring. C) Schematic illustration the construction of MTX-TA/Fe3+@HA for targeted RA treatment [183]. The image reproduced with the permission from Elsevier B.V. D) A multifunctional carrier for methotrexate delivery and bone repair of rheumatoid arthritis [148]. The image reproduced with the permission from The Royal Society of Chemistry. E) Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to target neutrophils [149]. The image reproduced with the permission from American Chemical Society. F) Schematic illustration of the shield and sword nano-soldiers for RA by multi-stage manipulation of neutrophils [187]. The image reproduced with the permission from Elsevier B·V.